|
Published by: Datamonitor
Published: Sep. 7, 2001 - 200 Pages
Table of Contents
EXECUTIVE SUMMARY
Scope
Datamonitor insight into the cancer hormonals market
Key metrics
TABLE OF CONTENTS
MARKET DEFINITION
Market definition
Therapy classes covered
Disease indications
Class definitions
LHRH agonists
Anti-androgens
Anti-estrogens
Aromatase inhibitors
Progestagens
Historical development of hormonal agents
Hormonal class comparisons
Prostate cancer
Breast cancer
Key developments in hormonal drug class
New product launches/reformulation
New indications
Key patent expiries/generic competitions
Price cuts in Japan
Lupron court case
GLOBAL MARKET ANALYSIS
Hormonal market analysis by drug class
Overview of global hormonal market
Key trends in the global hormonal market
Class growth analysis
LHRH agonists
Overview of the global LHRH agonist market
Key trends in the global LHRH agonist market
Lupron/Leuplin
Zoladex
Anti-androgens
Overview of the global anti-androgen market
Key trends in the global anti-androgen market
Casodex
Eulexin/Odyne
Androcur
Anti-estrogens
Overview of the global anti-estrogen market
Key trends in the global anti-estrogen market
Nolvadex
Fareston
Aromatase inhibitors
Overview of the global aromatase inhibitor market
Key trends in the global aromatase inhibitor market
Arimidex
Femara
Lentaron
Aromasin
Progestagens
Overview of the global progestagens market
Key trends in the global progestagen market
Depo-Provera
Megace
2000 COUNTRY MARKET ANALYSIS
The significance of major countries in the global hormonal market
Overview of the global hormonal market
Country positioning in the hormonals market
Figure 32 below positions the seven major pharmaceutical markets according to three criteria:
Breakdown of the country markets by class
The US hormonals market analysis
Environmental drivers of the US market
Japan hormonals market analysis
Environmental drivers in Japan
France hormonals market analysis
Environmental drivers in France
Germany hormonals market analysis
Environmental drivers in Germany
Italy hormonals market
Environmental drivers in Italy
Spain hormonals market analysis
Environmental drivers in Spain
UK hormonals market
Environmental drivers in the UK
LIFECYCLE MANAGEMENT
Global drug class lifecycle in hormonals
Reformulations of cancer hormonal agents
New indications for cancer hormonal agents
Lifecycle management case studies
Lupron: reaching the maximum commercial potential
Casodex: new indications to counter generic erosion
Nolvadex: life extension through commercial agreement with Barr
MARKET FORECASTS
Forecasting methodology
Trends in the hormonals market to 2008
Forecast overview
Class forecast
SUPPORTING DATA
Treatment of breast and prostate cancer
Trends in the epidemiology of breast and prostate cancer
Incidence of breast and prostate cancer
Prevalence of breast and prostate cancer
Classification of breast and prostate cancer
Breast cancer
Prostate cancer
APPENDIX
List of tables
List of figures
LIST OF FIGURES
Introduction
Hypothesis formulation
Hypothesis testing
Data verification with key contacts
Quality control
Quantification of data reliability
Confidence ratings
Exchange rates
ABOUT DATAMONITOR
DATAMONITOR HEALTHCARE
CONTACT DETAILS
AbstractOne of the causes of prostate and breast cancers is an imbalance in testosterone and estrogen (male and female hormones) levels in the body. Controlling the levels of hormones through the use of hormonal agents thus plays a key role in treating patients affected by these cancers. As with other cancer types, if treated early, the chance of survival is high. However, since prostate and breast cancer are two of the most prevalent cancers, affecting some 1.7 million males and 2.3 million females across seven major markets in 2000, respectively, these cancers remain leading causes of death. As a result of this large patient population, the cancer hormonals market should be an attractive target for pharmaceutical companies to pursue in terms of R&D. However, the market remains stagnant, with a distinct lack of competition with different classes dominated by few drugs. Market Dynamics 2001: Hormonals report examines the current hormonal products and the key factors that have and will have an impact on the competitive dynamics of the whole market. These factors are then analyzed in subsequent sections to forecast the sales revenues of hormonals products over the period 2001-2008.
Get Full Details About This Report >>
|
